Effect of serine-type protease of Candida spp. isolated from linear gingival erythema of HIV-positive children: Critical factors in the colonization

Journal of Oral Pathology and Medicine

Volumn 39, Issue 10, 2010, Pages 753-760

  Portela, Maristela B ^a   Souza, Ivete P R ^a   Abreu, Celina M ^a   Bertolini, Martinna ^a   Holandino, Carla ^a   Alviano, Celuta S ^a   Santos, André L S ^a   Soares, Rosangela M A ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Candida spp.; Candidiasis; Children; HIV infection; Protease

Indexed keywords

BOVINE SERUM ALBUMIN; FIBRONECTIN; FLUORIDE; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN G; LAMININ; PHENYLMETHYLSULPHONYL FLUORIDE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SODIUM DIHYDROGEN PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA TROPICALIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ISOLATION; ENZYME RELEASE; ENZYME SYNTHESIS; EPITHELIUM CELL; ERYTHEMA; FEMALE; FUNGAL COLONIZATION; FUNGAL STRAIN; GINGIVA DISEASE; GINGIVA ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CANDIDA; CANDIDIASIS, ORAL; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; COCULTURE TECHNIQUES; EPITHELIAL CELLS; ERYTHEMA; FEMALE; GINGIVAL DISEASES; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; PHENYLMETHYLSULFONYL FLUORIDE; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS;

EID: 77958585305     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00906.x     Document Type: Article

References (48)

1. Faucci A. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988; 239: 617.
2. Barr CE, Torosian JP. Oral manifestations in patients with AIDS or AIDS-related complex. Lancet 1986; 2: 288.
3. Ramos-Gomez FJ, Flaitz C, Catapano P, et al. Classification, diagnostic criteria, and treatment recommendations for orofacial manifestations in HIV-infected pediatric patients. J Clin Pediatr Dent 1999; 23: 85-96.
4. Pinheiro RS, França TT, Ribeiro CMB, Leão JC, Souza IPR, Castro GF. Oral manifestations in human immunodeficiency virus infected children in highly active antiretroviral therapy era. J Oral Pathol Med 2009; 38: 613-22.
5. Barasch A, Safford MM, Catalanotto FA, Fine DH, Katz RV. Oral soft tissue manifestations in HIV-positive vs. HIV-negative children from an inner city population: a two-year observational study. Pediatr Dent 2000; 22: 215-20.
6. Velegraki A, Nicolatou O, Theodoridou M, Mostrou G, Legakis N. Paediatric AIDS - related linear gingival erythema: a form of erythematous candidiasis? J Oral Pathol Med 1999; 28: 178-82.
7. Ramos-Gomez FJ, Petru A, Hilton JF, Canchola AJ, Wara D, Greenspan JS. Oral manifestations and dental status in paediatric HIV infection. Int J Paediatr Dent 2000; 10: 3-11.
8. Samaranayake LP. Oral mycoses in HIV infection. Oral Surg Oral Med Oral Pathol 1992; 73: 171-80.
9. Sullivan DJ, Henman MC, Moran GP, et al. Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species. J Med Microbiol 1996; 44: 399-408.
10. Naglik J, Albrecht A, Bader O, Hube B. Candida albicans proteases and host/pathogen interaction. Cell Microbiol 2004; 6: 915-26.
11. Rüchel R. On the role of proteases from Candida albicans in the pathogenesis of acronecrosis. Zbl Bakt Hyg Orig 1983; 255: 524-36.
12. Kaminishi H, Hagihara Y, Tanaka T, Cho T. Degradation of bovine Achilles tendon collagen by Candida albicans protease. J Med Vet Mycol 1988; 26: 315-8.
13. Rüchel R. Properties of a purified protease from the yeast Candida albicans. Biochim Biophys Acta 1981; 659: 99-113.
14. Negi M, Tsuboi R, Matsui T, Ogawa H. Isolation and characterization of protease from Candida albicans: substrate specificity. J Invest Dermatol 1984; 83: 32-6.
15. Remold H, Fasold H, Staib F. Purification and characterization of a proteolytic enzyme from Candida albicans. Biochim Biophys Acta 1968; 167: 399-406.
16. Borg-von Zepelin M, Rüchel R. Expression of extracellular acid protease by proteolytic Candida spp during experimental infection of oral mucosa. Infect Immun 1988; 56: 626-31.
17. Tsuboi R, Kurita Y, Negi M, Ogawa H. A specific inhibitor of keratinolytic protease from Candida albicans could inhibit cell growth of Candida albicans. J Invest Dermatol 1985; 85: 438-40.
18. Klotz SA, Drutz DJ, Harrison JL, Huppert M. Adherence and penetration of vascular endothelium by Candida yeast. Infect Immun 1983; 42: 374-84.
19. Cutler JE. Putative Virulence factors of Candida albicans. Annu Rev Microbiol 1991; 45: 187-218.
20. Costa EMB, Dos Santos ALS, Cardoso AS, et al. Heterogeneity of metallo and serine extracellular proteases in oral clinical isolates of Candida albicans in HIV-positive and healthy children from Rio de Janeiro, Brazil. FEMS Immunol Med Microbiol 2003; 38: 173-80.
21. Santos ALS, Carvalho IM, Silva BA, Portela MB, Alviano CS, Soares RMA. Secretion of serine protease by a clinical strain of Candida albicans: influence of growth conditions and cleavage of human serum proteins and extracellular matrix components. FEMS Immunol Med Microbiol 2006; 46: 209-20.
22. Santos ALS, Soares RMA. Candida guilliermondii isolated from HIV-infected human secretes a 50 kDa serine proteinase that cleaves a broad spectrum of proteinaceous substrates. FEMS Immunol Med Microbiol 2005; 43: 13-20.
23. Yarrow D. Methods for the isolation, maintenance and identification of yeasts. In: Kurtzman CP, Fell JW, eds. The yeasts, a taxonomic study, 4th edn. Amsterdam, The Netherlands: Elsevier, 1998; 77-100.
24. Lowry OH, Rosebrogh NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
25. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrilamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102: 196-202.
26. Puccia R, Carmona AK, Gesztesi JL, Juliano L, Travassos LR. Exocellular proteolytic activity of Paracoccidioides brasiliensis: cleavage of components associated with the basement membrane. Med Mycol 1998; 36: 345-8.
27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
28. Zambon JJ, Reynolds HS, Genco RJ. Studies of the subgengival microflora in patients with acquired immunodeficiency syndrome. J Periodontol 1990; 61: 699-704.
29. Lucht E, Heimdahl A, Nord CE. Periodontal disease in HIV-infected patients in relation to lymphocyte subsets and specific micro-organisms. J Clin Periodontol 1991; 18: 252-6.
30. Nakou M, Kamma J, Gargalianos P, et al. Periodontal microflora of HIV-infected patients with periodontitis. Anaerobe 1997; 3: 97-102.
31. Jabra-Rizk MA, Falkler WA Jr, Baqui AA, Kelly JI, Meiller TF. Cell surface hydrophobicity-associated adherence of Candida dubliniensis to human buccal epithelial cells. Rev Iberoam Micol 2001; 18: 17-22.
32. Portela MB, Souza IP, Costa EM, Hagler AN, Soares RMA, Santos ALS. Differential recovery of Candida species from subgingival sites in human immunodeficiency virus-positive and healthy children from Rio de Janeiro, Brazil. J Clin Microbiol 2004; 42: 5925-7.
33. Teanpaisan R, Nittayananta W. Prevalence of Candida species in AIDS patients and HIV-free subjects in Thailand. J Oral Pathol Med 1998; 27: 4-7.
34. Vargas KG, Joly S. Carriage frequency, intensity of carriage and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. J Clin Microbiol 2002; 40: 341-50.
35. Sweet SP. Oral candidiasis in HIV infection. J Dent Res 1994; 73: 792.
36. Martinez M, Lopez-Ribot JL, Kikpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol 2002; 40: 3135-9.
37. De Bernardis F, Arancia S, Morelli L, et al. Evidence that members of the secretory aspartyl protease gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 1999; 179: 201-8.
38. Larcher G, Bouchara JP, Annaix V, Symoens F, Chabasse D, Tronchin G. Purification and characterization of a fibronogenolytic serine protease from Aspergillus fumigatus culture filtrate. FEBS Lett 1992; 308: 65-9.
39. Larcher G, Cimon B, Symoens F, Tronchin G, Chabasse D, Bouchara JP. A 33 kDa serine protease from Scedosporium apiospermum. Biochem J 1996; 315: 119-26.
40. Rodrigues ML, Dos Reis FCG, Puccia R, Travassos LR, Alviano C. Cleavage of human fibronectin and other basement membrane-associated proteins by a Cryptococcus neoformans serine protease. Microb Pathog 2003; 34: 65-71.
41. Robison BW, Venaille TJ, Mendis AH, McAleer R. Allergens as proteases: an Aspergillus fumigatus protease directly induces human epithelial cell detachment. J Allergy Clin Immunol 1990; 86: 726-31.
42. Montenegro MR, Franco M. Pathology. In: Franco M, Lacaz CS, Restrepo-Moreno A, Del Negro G, eds. Paracoccidioidomycosis. Boca Raton, FL: CRC Press, 1993; 131-50.
43. Nogueira de Melo ACN, Dornelas-Ribeiro M, De Souza EP, Macrae A, Fracalanzza SE, Vermelho AB. Peptidase profiles from non-albicans Candida spp. isolated from the blood of a patient with chronic myeloid leukemia and another with sickle cell disease. FEMS Yeast Res 2007; 6: 1004-12.
44. Vermelho AB, Mazotto AM, Nogueira de Melo AC, et al. Identification of a Candida parapsilosis strain producing extracellular serine peptidase with keratinolytic activity. Mycopathologia 2010; 169: 57-65.
45. Pärnänen P, Kari K, Virtanen I, Sorsa T, Meurman JH. Human laminin-332 degradation by Candida proteinases. J Oral Pathol Med 2008; 37: 329-35.
46. Koga-Ito CY, Lyon JP, Vidotto V, De Resende MA. Virulence factors and antifungal susceptibility of Candida albicans from oral candidosis patients and control individuals. Mycopathologia 2006; 161: 219-23.
47. Gozalbo D, Roig P, Villamón E, Gil ML. Candida and candidiasis: the cell wall as a potential molecular target for antifungal therapy. Curr Drug Targets Infect Disord 2004; 4: 117-35.
48. Yang YL. Virulence factors of Candida species. J Microbiol Immunol Infect 2003; 36: 223-8.